Glatopa

Active Ingredient(s): Glatiramer Acetate
FDA Approved: * April 16, 2015
Pharm Company: * SANDOZ INC
Category: Multiple Sclerosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Glatopa Overview

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone) is an immunomodulator medication currently used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of ...

Read more Glatopa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glatiramer_acetate

Recent Glatopa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Glatopa: (2 results)

Sorted by National Drug Code

• 0781-3234 Glatopa 20 mg/ml Subcutaneous Injection, Solution by Sandoz Inc
• 0781-3250 Glatopa 40 mg/ml Subcutaneous Injection, Solution by Sandoz Inc

Other drugs which contain Glatiramer Acetate or a similar ingredient: (2 results)

• COPAXONE Glatiramer2 discussions
• GLATIRAMER